0RC7 Stock Chart & Stats
kr34.84
kr0.44(1.28%)
At close: 4:00 PM EDT
kr34.84
kr0.44(1.28%)
Day’s Range― - ―
52-Week Rangekr23.57 - kr44.84
Previous CloseN/A
Volume20.86K
Average Volume (3M)9.76K
Market Cap
kr4.53B
Enterprise Valuekr4.01K
Total Cash (Recent Filing)kr552.81M
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 05, 2026EPS Estimate
5.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.86
Shares Outstanding101,763,220
10 Day Avg. Volume5,504
30 Day Avg. Volume9,756
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr103.00Price Target Upside195.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.24
Revenue Forecast (FY)kr467.18M
Bulls Say, Bears Say
Bulls Say
Strategic Licensing Strengthens LiquidityThe SERB transaction materially improves funding capacity and extends the runway ahead of potential U.S. approval. Greater liquidity can support commercialization, regulatory work and pipeline development while reducing immediate dependence on external financing.
Strong Confirmatory Clinical EvidenceLarge improvements in kidney function and lower dialysis dependency strengthen imlifidase’s clinical differentiation. Positive PAES data also support conversion to full European approval, potentially broadening the product’s long-term commercial position.
U.S. Launch And Market Expansion OpportunityA defined U.S. regulatory timetable and preparations across high-volume transplant centers create a credible expansion path beyond Europe. Approval could unlock a sizeable underserved market and diversify future revenue sources for the company.
Bears Say
Persistent Losses And Cash BurnSevere operating losses and consistently negative cash generation indicate that the business has not yet reached sustainable scale. Continued investment in commercialization and development may require substantial funding unless revenue growth and operating leverage improve.
Negative Equity And High DebtNegative equity combined with sizeable debt reduces financial flexibility and increases refinancing and solvency risk while losses persist. Although the SERB proceeds improve liquidity, the underlying capital structure remains a material long-term constraint.
Commercial And Clinical Execution RisksFlat European sales alongside rising launch costs could prolong operating losses during expansion. The higher observed antibody-mediated rejection rate, despite being manageable, may complicate adoption, reimbursement discussions and regulatory execution.
Hansa Biopharma AB News
0RC7 FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest share price was kr23.57 and its highest was kr44.84 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr4.53B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Nov 05, 2026 which is in 64 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Jul 22, 2026. The company reported -kr2.56 earnings per share for the quarter, missing the consensus estimate of -kr0.337 by -kr2.223.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 5.76.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr2.56 in its last earnings report, missing expectations of -kr0.337. Following the earnings report the stock price went up 0.395%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in GB:0RC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
0RC7 Stock 12 Month Forecast
Average Price Target
kr103.00
▲(195.64% Upside)
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Cantargia AB
―